Astellas Hits Walls In Fending Off Prograf Generics; Options Limited

WASHINGTON - Astellas' last ditch efforts to prevent the launch of Sandoz' generic Prograf (tacrolimus) failed last week, and as the company "evaluates its next course of action" for its top-selling product, its options do not look promising